COMPANY PROFILE

Surface Pharmaceuticals

Explore full profile

Innovative ophthalmic solutions enhancing eye care with advanced therapeutics

Pleasanton, United StatesFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Surface Pharmaceuticals

Surface Pharmaceuticals operates in the ophthalmology sector, focusing on developing and commercializing innovative treatments for eye diseases. The company primarily serves patients and healthcare providers in the ocular surgery, glaucoma, and dry eye disease markets. Surface Pharmaceuticals employs a business model centered around research and development, leveraging scientific expertise to create advanced therapeutics. Revenue is generated through the sale of these specialized ophthalmic drugs, which are designed to improve patient outcomes and address unmet medical needs in eye care. The company aims to provide affordable and effective solutions, positioning itself as a leader in the ophthalmic pharmaceutical industry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Pleasanton, United States
Open positions: None listed
Dealroom signal: 20.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Arts & Culture, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCEquity / VC	Jun 2021	$5.8M	$23M	Undisclosed	—
SERIES A✓Equity / VC	Jul 2018	$21M	$84M	Visionary Ventures	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Surface Pharmaceuticals website traffic

Latest recorded traffic for Surface Pharmaceuticals is 150 monthly website visits, up 66.7% over the last three months.

Latest monthly visits150 3-month web change+66.7%

Monthly website visitsOct 2017–Nov 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OMOM1A leading health outcomes and registries company focused on the measurement, comparison, and prediction of treatment outcomes	Boston, United States	Operational	96	$172M	$340M
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
LTLiMM TherapeuticsDeveloper of antibiotics and immunomodulators, harnessing harnessing the molecular cross-talk between neuronal and innate lymphoid cells	Paris, France	Closed
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
CPCStone PharmaceuticalsBio-pharmaceutical company	Huangpu, China	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational